FantasticSearch

Scroll to: TopResults

Explore European Union Legislation by Asking a Legal Question

assisted-checkbox

filter-instruction-1
positive-filters
negative-filters
act-filter tabs-all

parameters-title

query

assisted-checkbox:

result-title

total 2

Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance)

article  annex_III

CELEX:  02007R1394-20190726

Labelling of outer/immediate packaging referred to in Article 11 (a) The name of the medicinal product and, if appropriate, an indication of whether it is intended for babies, children or adults; the international non-proprietary name (INN) shall be included, or, if the product has no INN, the common name;
(b) A description of the active substance(s) expressed qualitatively and quantitatively, including, where the product contains cells or tissues, the statement ‘This product contains cells of human/animal [as appropriate{] origin’ together with a short description of these cells or tissues and of their specific origin, including the species of animal in cases of non-human origin;
(c) The pharmaceutical form and, if applicable, the contents by weight, by volume or by number of doses of the product;
(d) A list of excipients, including preservative systems;
(e) The method of use, application, administration or implantation and, if necessary, the route of administration. If applicable, space shall be provided for the prescribed dose to be indicated;
(f) A special warning that the medicinal product must be stored out of the reach and sight of children;
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance)

article  annex_III

CELEX:  02007R1394-20190726

(g) Any special warning necessary for the particular medicinal product;
(h) The expiry date in clear terms (month and year; and day if applicable);
(i) Special storage precautions, if any;
(j) Specific precautions relating to the disposal of unused medicinal products or waste derived from medicinal products, where appropriate, as well as reference to any appropriate collection system in place;
(k) The name and address of the marketing authorisation holder and, where applicable, the name of the representative appointed by the holder to represent him;
(l) Marketing authorisation number(s);
(m) The manufacturer’s batch number and the unique donation and product codes referred to in Article 8(2) of Directive 2004/23/EC;
(n) In the case of advanced therapy medicinal products for autologous use, the unique patient identifier and the statement ‘For autologous use only’.